Ibio Inc

Ibio Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.05
  • Today's Change-0.41 / -16.67%
  • Shares traded4.23k
  • 1 Year change-79.96%
  • Beta-3.3177
Data delayed at least 15 minutes, as of Mar 22 2023 20:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

iBio, Inc. is a developer of next-generation biopharmaceuticals using its proprietary artificial intelligence (AI)-Driven Discovery Platform and FastPharming Manufacturing System. The Company is focusing its technologies on the research and development of novel products at its Drug Discovery Center in California. The Company through its FastPharming Manufacturing System and GlycaneeringSM Technologies develop its portfolio of proprietary biologic drug candidates. The Company operates through two segments: Biopharmaceuticals, and Bioprocessing. Its Biopharmaceuticals segment is engaged in large molecule discovery, development, and licensing activities. Its Bioprocessing segment is engaged in contract development and manufacturing services for recombinant proteins. Its pipeline includes IBIO-100, IBIO-101, IBIO-202, and IBIO-400. Its subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringSM Development Services.

  • Revenue in USD (TTM)2.00m
  • Net income in USD-47.54m
  • Incorporated2008
  • Employees105.00
  • Location
    Ibio Inc600 Madison Avenue, Suite 1601NEW YORK 10022-1737United StatesUSA
  • Phone+1 (302) 355-0650
  • Fax+1 (302) 356-1173
  • Websitehttps://www.ibioinc.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
IBIO:ASQ since
Rubryc Therapeutics IncDeal completed21 Sep 202221 Sep 2022Deal completed-75.88%6.00m
Data delayed at least 15 minutes, as of Mar 22 2023 20:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Rasna Therapeutics Inc0.00-561.79k29.25m0.00---------0.0045-0.00450.00-0.010.00-------1,194.79-84.68---486.62-----------0.642--------21.62------
Lipocine Inc500.00k-10.76m29.30m17.00--0.8221--58.59-0.1212-0.12120.00560.40260.0111--3.0529,411.77-23.90-38.07-26.01-45.95-----2,151.73-330.89----0.00---96.90---1,595.88------
Vistagen Therapeutics Inc-363.90k-63.71m29.35m32.00--1.34-----0.3083-0.3083-0.00180.0999-0.006-----10,108.33-105.97-70.25-116.32-76.59-------5,704.43----0.0203--1.78-2.37-15.09---3.47--
Zivo Bioscience Inc0.00-9.62m29.67m10.00--19.47-----1.04-,265.10---819.800.1994---100.00---0.633------
Sio Gene Therapies Inc0.00-50.27m30.07m12.00--0.6148-----0.6835-0.68350.000.66120.00----0.00-61.20-79.80-67.41-105.83-----------3,350.67---------121.70--45.93--
Arca Biopharma Inc0.00-9.93m30.41m5.00--0.7296-----0.6888-0.68880.002.890.00----0.00-20.26-35.30-21.26-37.94------------0.00------48.63---7.79--
Ibio Inc2.00m-47.54m30.43m105.00--1.62--15.18-5.30-8.850.22211.520.0225--3.7119,085.71-53.35-32.33-66.90-35.4496.86---2,372.46-1,396.73---173.600.493--0.506143.33-114.73--48.82--
PaxMedica Inc0.00-3.35m30.45m2.00--12.48-----0.2842-0.28420.000.20280.00----0.00-85.41-----------------5,662.630.0615-------10.01------
Mannatech Inc142.37m4.61m30.63m246.007.201.654.850.21522.272.2770.129.932.452.15691.10578,723.607.924.1316.897.8878.0079.083.241.670.737511.390.025756.855.52-2.3957.20---22.2423.56
Kala Pharmaceuticals Inc3.89m-44.82m30.69m34.00--1.36--7.88-30.16-30.162.5711.120.03440.59270.5009114,470.60-39.62-54.04-54.95-63.2234.22---1,151.64-1,642.633.35-12.380.6935---65.37--68.57---8.20--
Axcella Health Inc0.00-76.08m30.80m59.00---------1.66-1.660.00-0.14340.00----0.00-152.75---218.17-------------26.511.43-------14.33------
Correlate Infrastructure Partners Inc403.55k-2.68m31.71m11.00------78.57-0.0825-0.08250.007-0.01320.2844-------188.66-65.78----20.2631.50-663.41-195.160.3337-2.291.82---42.33-40.1251.05------
Eledon Pharmaceuticals Inc0.00-38.39m31.78m12.00--0.2252-----2.66-2.660.0010.260.00----0.00-23.50-29.03-24.26-30.02------------0.00-------51.27------
Freeline Therapeutics Holdings PLC (ADR)0.00-100.67m31.84m235.00--0.4642-----2.20-
Corvus Pharmaceuticals Inc0.00-40.73m31.89m28.00--0.493-----0.8746-0.87460.001.390.00----0.00-40.79-39.16-46.71-43.08-----------4.440.00-------621.28---70.40--
Data as of Mar 22 2023. Currency figures normalised to Ibio Inc's reporting currency: US Dollar USD

Institutional shareholders

16.76%Per cent of shares held by top holders
HolderShares% Held
Sabby Management LLCas of 31 Dec 2022490.45k3.97%
The Vanguard Group, Inc.as of 31 Dec 2022472.55k3.82%
Renaissance Technologies LLCas of 31 Dec 2022381.60k3.09%
BlackRock Fund Advisorsas of 31 Dec 2022269.24k2.18%
Susquehanna Financial Group LLLPas of 31 Dec 2022134.85k1.09%
Geode Capital Management LLCas of 31 Dec 202276.29k0.62%
Dimensional Fund Advisors LPas of 31 Dec 202273.60k0.60%
Millennium Management LLCas of 31 Dec 202270.70k0.57%
Two Sigma Investments LPas of 31 Dec 202253.46k0.43%
Warberg Asset Management LLCas of 31 Dec 202250.00k0.40%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.